Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-0.60% $13.30
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 72.92 mill |
EPS: | -17.16 |
P/E: | -0.780 |
Earnings Date: | Mar 27, 2024 |
SharesOutstanding: | 5.48 mill |
Avg Daily Volume: | 0.0297 mill |
RATING 2024-03-28 |
---|
B- |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Sell | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | |||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.780 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.13x |
Company: PE -0.780 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$1.011 (-92.40%) $-12.29 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 12.43 - 14.07 ( +/- 6.17%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-13 | Cook Robert Donald Ii | Buy | 0 | |
2024-01-18 | Schornstein Alexander | Buy | 345 086 | Common Stock |
2024-01-17 | Schornstein Alexander | Buy | 299 994 | Common Stock |
2023-12-07 | Cihlar Tomas | Buy | 0 | |
2023-11-21 | Schornstein Alexander | Buy | 100 000 | Common Stock |
INSIDER POWER |
---|
64.64 |
Last 95 transactions |
Buy: 4 317 018 | Sell: 737 887 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $13.30 (-0.60% ) |
Volume | 0.0301 mill |
Avg. Vol. | 0.0297 mill |
% of Avg. Vol | 101.28 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.